Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Different Volumes of Durolane in Knee OA

Lead Sponsor:

Galderma R&D

Conditions:

Knee Osteoarthritis

Eligibility:

All Genders

40-85 years

Phase:

PHASE2

Brief Summary

The purpose of the study is to assess the safety and efficacy profiles of new single-injection volumes of Durolane in patients with knee OA.

Detailed Description

To assess the safety and efficacy profiles of different volumes of Durolane in patients with knee OA and compare with the current standard single-injection of the product. The study aims to investigat...

Eligibility Criteria

Inclusion

  • Subject (female or male)
  • 40-85 years of age
  • Unilateral knee pain fulfilling American College of Rheumatology (ACR) criteria for diagnosis of osteoarthritis(OA)
  • Radiographic evidence of OA in the study knee
  • WOMAC pain score of 7-17 in the study knee
  • WOMAC pain score of 2-3 in the study knee (WOMAC Likert 3.1 A1)
  • Subject normally active
  • Subject has attempted but not responded adequately to previous non-pharmacological therapy(ies)and to simple analgetics
  • Subject cooperative and able to communicate effectively with the investigators
  • Body mass index ≤ 35 kg/m2;
  • Signed informed consent obtained

Exclusion

  • Knee effusion
  • Contralateral knee OA
  • Clinically significant joint pain from joints other than the knee
  • Previous intra-articular steroid injection into the study knee within the last 6 months
  • Previous intra-articular Hyaluronic Acid (HA) injection into the study knee within the last 9 months
  • Previous allergic type reaction to a HA product
  • Treatment with analgesics other than paracetamol (acetaminophen) (including topical agents for the knee) within 5 half lives of the drug prior to the baseline visit
  • Use of analgesics 48 hours preceding the baseline visit
  • Use of systemic glucocorticosteroids (excluding inhaled steroids) within the last 3 months
  • Treatment with glucosamine/chondroitin sulfate initiated within the past 3 months
  • Change in physical therapy for the knee within the last three months
  • Arthroscopy or other surgical procedure in the study knee within the past 12 months
  • Serious injuries to the study knee in the past
  • Any planned arthroscopy or other surgical procedure during the study period
  • Previous history or presence of active septic arthritis
  • Active skin disease or infection in the area of the injection site
  • Systemic active inflammatory condition or infection
  • Bleeding diathesis or use of anticoagulants
  • History of drug or alcohol abuse within 6 months
  • Any medical condition that in the opinion of the investigator makes the subject unsuitable for inclusion
  • Pregnant or breastfeeding woman or woman of childbearing potential not practicing adequate contraception
  • Involvement in other clinical trials

Key Trial Info

Start Date :

January 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2011

Estimated Enrollment :

68 Patients enrolled

Trial Details

Trial ID

NCT01265459

Start Date

January 1 2011

End Date

November 1 2011

Last Update

September 22 2022

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Torsten Adalberth

Malmo, Sweden, 211 36

2

Christian Akermark

Stockholm, Sweden, 111 35

3

Johan Isacson

Upplands Vasby, Sweden, 194 89